ELOXX PHARMACEUTICALS, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent
ELOXX PHARMACEUTICALS, INC. (ELOX) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent of -2.40% for the 12-month period ending 2025-12-31, per its S-1 filed 2026-09-11.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2026-09-11
- ELOXX PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2017 was -0.40%.
- ELOXX PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2016 was -0.70%.
- ELOXX PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2015 was -3.00%.
- ELOXX PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2014 was 0.00%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month as first filed |
|---|---|---|
| 2025-12-31 | -2.40% S-1 · filed 2026-09-11 | 2.40% 10-K · filed 2026-03-17 |
| 2024-12-31 | -8.90% S-1 · filed 2026-09-11 | 8.90% 10-K · filed 2026-03-17 |
| 2023-12-31 | -20.10% S-1 · filed 2026-09-11 | 20.10% 10-K · filed 2026-03-17 |
| 2017-06-30 | -0.40% 10-K · filed 2017-10-13 | |
| 2016-06-30 | -0.70% 10-K · filed 2017-10-13 | |
| 2015-06-30 | -3.00% 10-K · filed 2017-10-13 | |
| 2014-06-30 | 0.00% 10-K · filed 2016-10-13 | |
| 2013-06-30 | 0.00% 10-K · filed 2015-10-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Tevogen Inc. (TVGN) | United States | $0.049B |